Seeing Is Believing
AMAM is currently covered by 6 analysts with an average price target of $34.2. This is a potential upside of $6.2 (22.14%) from yesterday's end of day stock price of $28.
Ambrx Biopharma . American Depositary Shares's activity chart (see below) currently has 3 price targets and 23 ratings on display. The stock rating distribution of AMAM is 73.68% BUY and 26.32% HOLD.
Analysts average stock forecasts to be materialized ratio is 75% with an average time for these price targets to be met of 101 days.
Highest price target for AMAM is $28, Lowest price target is $22, average price target is $34.2.
Most recent stock forecast was given by JOEL BEATTY from BAIRD on 16-Jan-2024. First documented stock forecast 28-Feb-2022.
Currently out of the existing stock ratings of AMAM, 14 are a BUY (73.68%), 5 are a HOLD (26.32%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$22
$-6 (-21.43%)
$22
11 months 2 days ago
(16-Jan-2024)
5/6 (83.33%)
$-5.68 (-20.52%)
113
Hold
$15
11 months 8 days ago
(10-Jan-2024)
3/3 (100%)
$3.28 (27.99%)
65
Hold
$28
$26
11 months 9 days ago
(09-Jan-2024)
2/2 (100%)
$0.45 (1.63%)
105
Hold
$9
$-19 (-67.86%)
$10
1 years 1 months 3 days ago
(15-Nov-2023)
2/3 (66.67%)
$-0.45 (-4.76%)
181
Buy
$32
$4 (14.29%)
$33
1 years 1 months 4 days ago
(14-Nov-2023)
0/3 (0%)
$22.99 (255.16%)
What is AMAM (Ambrx Biopharma . American Depositary Shares) average time for price targets to be met?
Which analyst has the current highest performing score on AMAM (Ambrx Biopharma . American Depositary Shares) with a proven track record?
Which analyst has the current lower performing score on AMAM (Ambrx Biopharma . American Depositary Shares) with a proven track record?
Which analyst has the most public recommendations on AMAM (Ambrx Biopharma . American Depositary Shares)?
Which analyst is the currently most bullish on AMAM (Ambrx Biopharma . American Depositary Shares)?
Which analyst is the currently most reserved on AMAM (Ambrx Biopharma . American Depositary Shares)?